论文部分内容阅读
目的：探讨白细胞介素6（IL-6）在格林-巴利综合征（GBS）发病中的作用及免疫抑制性药物（雷公藤多甙）对其的影响。方法：按Asbury标准选择GBS患者43例，以分层随机原则分为2组，分别用肾上腺皮质类固醇（对照组）和雷公藤多甙（治疗组）治疗，并取静脉血和脑脊液配对标本2ml，用双抗体夹心ELISA法测定IL－6。结果：（1）治疗前GBS患者血清、脑脊液中IL－6测定水平明显高于正常值；（2）治疗前GBS患者脑脊液中IL-6与病情严重程度分级相关密切；（3）治疗后两组临床症状均有不同程度的改善，而治疗组优于对照组（P＜0．05），血清IL－6降低的程度亦是治疗组明显（P＜0.05）。结论：脑脊液中IL－6可作为GBS病情严重程度判断的指标之一。雷公藤多甙抑制脑脊液患者的异常免疫应答优于肾上腺皮质类固醇。
Objective: To investigate the role of interleukin-6 (IL-6) in the pathogenesis of Guillain-Barre syndrome (GBS) and the effect of immunosuppressive drugs (TWP) on it. Methods: Forty-three patients with GBS were selected according to Asbury criteria. The patients were divided into two groups according to stratified randomization principle. The rats were treated with adrenal corticosteroid (control group) and tripterygium glycosides (treated group) respectively. The venous blood and cerebrospinal fluid IL-6 was measured by double antibody sandwich ELISA. Results: (1) The level of IL-6 in serum and cerebrospinal fluid of patients with GBS before treatment was significantly higher than normal; (2) IL-6 in cerebrospinal fluid of patients with GBS before treatment was closely related to the grading of severity of disease; (3) Group clinical symptoms were improved to varying degrees, while the treatment group was better than the control group (P <0.05), the level of serum IL-6 decreased also significantly (P <0.05). Conclusion: IL-6 in cerebrospinal fluid can be used as one of the indicators to judge the severity of GBS. Tripterygium glycosides inhibit CSF abnormalities in patients with immune response superior to adrenal corticosteroids.